Phase 2 trial of SL-701, a novel immunotherapy comprised of synthetic short peptides against GBM targets
Phase 2 trial of SL-701, a novel immunotherapy comprised of synthetic short peptides against GBM targets IL-13Rα2, EphA2, and Survivin, in adults with second-line recurrent GBM. SNO 2017. Oral Presentation
